SangStat
SangStat is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at SangStat.
SangStat is a company.
Key people at SangStat.
Key people at SangStat.
SangStat Medical Corporation was a global biopharmaceutical company focused on discovering, developing, and marketing therapeutic products for immunology, transplantation medicine, hematology/oncology, and autoimmune disorders.[1][2] Its primary marketed products included Thymoglobulin for treating acute kidney transplant rejection, Gengraf (cyclosporine capsules) as an immunosuppressive agent, Lymphoglobuline for preventing transplant rejection and treating conditions like aplastic anemia, and Celsior as an organ storage solution.[1] The company served transplant patients, healthcare providers, and hospitals worldwide through direct sales in Europe, the US, and Canada, plus global distributors, addressing critical needs in graft acceptance and organ transplantation while researching items like RDP58 for Crohn's disease and ulcerative colitis.[1][3]
Founded in 1988 and headquartered in Fremont, California, SangStat achieved financial milestones like a $595.7M market cap, $48.9M gross profit, and $80.1M in cash equivalents before its acquisition by Genzyme Corp. on September 10, 2003.[1][5]
SangStat Medical Corporation was established in 1988 as a biotechnology firm building expertise in transplantation medicine.[1] It emerged during a period of advancing immunosuppressive therapies, focusing initially on products to improve graft acceptance and organ transplantation outcomes.[3] Key early developments included pharmaceuticals like Thymoglobulin and Lymphoglobuline, which gained traction for treating rejection in kidney, heart, pancreas, and liver transplants, as well as related conditions.[1]
Pivotal moments included expanding into marketed products like Gengraf and Celsior, alongside R&D on next-generation cyclosporine and RDP58.[1] By the early 2000s, SangStat had built a global presence with sales forces and distributors, competing with giants like Novartis and Johnson & Johnson, before Genzyme acquired it in 2003.[1]
SangStat rode the late-1980s to early-2000s wave of biotechnology advances in transplantation immunology, a trend driven by rising organ transplant volumes and demand for safer immunosuppressants amid shortages and rejection risks.[1][3] Timing was ideal post-cyclosporine breakthroughs (e.g., via Gengraf), capitalizing on market forces like aging populations and improved surgical techniques boosting transplant needs.[1]
It influenced the ecosystem by pioneering products like Thymoglobulin, setting standards for rejection treatment and organ preservation, while competing with pharma leaders fostered innovation in autoimmune and hematology spaces.[1][2] Post-acquisition by Genzyme, its assets integrated into larger portfolios, extending impact on modern transplant therapies.[1]
SangStat's legacy endures through its products, now under Genzyme (Sanofi), continuing to support transplant medicine over two decades post-acquisition.[1] Future trends like personalized immunosuppressants and xenotransplantation could revive similar innovations, but as a historical player, its influence evolves via inherited pipelines rather than independent growth. This early biotech pioneer's focus on immunology underscores timeless needs in transplantation, tying back to its role in transforming patient outcomes from a Fremont startup to global contender.[1][3]
